Advancing Care for Patients During & After Treatment: Molecular Residual Disease Strategic Planning Group

Presented by: Anne-Marie Martin, PhD, GSK

BLOODPAC

The Challenge

Identify and address barriers to the implementation of molecular residual disease (MRD) in solid tumors in non-metastatic disease and develop and resource projects to address these challenges in the near and long term.

5-Year Goal

Validate MRD as an early endpoint in solid tumors.

BloodPAC's successes position us to address the challenges of MRD in solid tumors

Initiative	Impact in the field
MRD Analytical Validation Working Group	Drafting a set of generic analytical validation protocols for MRD assays with FDA feedback
JFDI Working Group	Successfully developed and characterized cfDNA reference materials for genotyping NGS assay
Recommended Data Elements Working Group (MTDEs)	Identified and published a common set of minimum core data elements recommended for all liquid biopsy studies
BloodPAC Data Commons	BloodPAC has established an open, publicly accessible data commons for the global liquid biopsy community

Project Roadmap

Short-term (1 year)	*Mid-term (2-3 years)*		*Long-term (4-5+ years)*
Develop a lexicon	Develop and characterize an "MRD-like" reference material	Identify key data elements	· Define clinical questions & endpoints · Develop protocols for intended uses · Run a prospective trial

BloodPAC's work fits within the work of other stakeholders

Strategic Planning Group Participants

- BMS
- C2i Genomics
- Foundation Medicine
- Freenome
- Friends of Cancer Research
- GSK
- Guardant Health
- Inivata
- LGC Group / SeraCare
- Merck
- Natera
- NIH / NCI
- Quest Diagnostics
- Tempus
- Thermo Fisher Scientific